ACLY Inhibition Rescues Alpha-Synuclein Autophagy

ACLY Inhibition Rescues Alpha-Synuclein-Impaired Autophagy

Overview

This mechanism describes how ATP citrate lyase (ACLY) inhibition rescues autophagy defects caused by pathogenic alpha-synuclein mutations in Parkinson's disease. Research has demonstrated that alpha-synuclein (α-Syn) mutations trigger a cascade involving ACLY activation, p300 mislocalization, and subsequent autophagy impairment—which can be rescued by pharmacological ACLY inhibition[@chung2025].

This pathway represents a novel therapeutic target linking metabolic dysregulation with protein homeostasis defects in synucleinopathies.

Molecular Mechanism

Step 1: Mutant Alpha-Synuclein Activates ACLY

Pathogenic mutations in the [SNCA](/genes/snca) gene (such as A53T, E46K, or H50Q) lead to increased activity of ATP citrate lyase (ACLY), the enzyme that converts citrate to acetyl-CoA in the cytoplasm. This activation represents an early molecular event in alpha-synuclein-induced neurotoxicity[@chung2025].

ACLY Function:

• Cytosolic enzyme that cleaves citrate to generate acetyl-CoA[@wellen2009]
• Links cellular metabolism to epigenetic regulation[@pietrocola2015]
• Provides acetyl-CoA for lipid synthesis and protein acetylation[@shih2021]
• Hyperactive in multiple neurodegenerative disease models[@baird2024]

α-Syn Mutation Effects:

• A53T (A53T) - Enhanced aggregation propensity, faster fibril formation[@conway2000]
• E46K (E46K) - Increased membrane binding, Lewy body formation[@perrin2003]
• H50Q (H50Q) - Reduced fibril stability, altered aggregation[@ghosh2013]

...

ACLY Inhibition Rescues Alpha-Synuclein-Impaired Autophagy

Overview

This mechanism describes how ATP citrate lyase (ACLY) inhibition rescues autophagy defects caused by pathogenic alpha-synuclein mutations in Parkinson's disease. Research has demonstrated that alpha-synuclein (α-Syn) mutations trigger a cascade involving ACLY activation, p300 mislocalization, and subsequent autophagy impairment—which can be rescued by pharmacological ACLY inhibition[@chung2025].

This pathway represents a novel therapeutic target linking metabolic dysregulation with protein homeostasis defects in synucleinopathies.

Molecular Mechanism

Step 1: Mutant Alpha-Synuclein Activates ACLY

Pathogenic mutations in the [SNCA](/genes/snca) gene (such as A53T, E46K, or H50Q) lead to increased activity of ATP citrate lyase (ACLY), the enzyme that converts citrate to acetyl-CoA in the cytoplasm. This activation represents an early molecular event in alpha-synuclein-induced neurotoxicity[@chung2025].

ACLY Function:

• Cytosolic enzyme that cleaves citrate to generate acetyl-CoA[@wellen2009]
• Links cellular metabolism to epigenetic regulation[@pietrocola2015]
• Provides acetyl-CoA for lipid synthesis and protein acetylation[@shih2021]
• Hyperactive in multiple neurodegenerative disease models[@baird2024]

α-Syn Mutation Effects:

• A53T (A53T) - Enhanced aggregation propensity, faster fibril formation[@conway2000]
• E46K (E46K) - Increased membrane binding, Lewy body formation[@perrin2003]
• H50Q (H50Q) - Reduced fibril stability, altered aggregation[@ghosh2013]

Step 2: ACLY Activation Drives Metabolic Rewiring

The increased ACLY activity results in elevated cytoplasmic acetyl-CoA levels, which has two major consequences[@chung2025]:

1. Global Histone Hypoacetylation:

• Increased acetyl-CoA fuels p300/CBP acetyltransferases[@lee2012]
• Paradoxically causes excessive acetylation of histones in some contexts[@kclimentcatalan2016]
• Leads to transcriptional dysregulation of autophagy genes[@pietrocola2015a]

2. LKB1 Acetylation and AMPK Inhibition:

• ACLY-derived acetyl-CoA increases acetylation of LKB1 (Liver Kinase B1)[@lan2011]
• LKB1 is a critical upstream kinase that activates AMPK[@hardie2012]
• Acetylation inhibits LKB1 activity[@lin2012]
• Results in reduced AMPK signaling[@mihaylova2011]

Step 3: p300 Mislocalization and Autophagy Impairment

The inhibition of AMPK leads to a critical downstream effect[@chung2025]:

Decreased Nuclear p300:

• AMPK normally promotes nuclear localization of p300[@bauer2019]
• With AMPK inhibited, p300 accumulates in the cytoplasm[@cheng2019]
• Nuclear p300 levels decline significantly[@yang2023]

Consequences of p300 Mislocalization:

• Reduced nuclear histone acetylation impairs transcription[@grunstein1997]
• Autophagy gene expression is suppressed[@fllgrabe2014]
• Decreased transcription of LC3, ATG5, ATG7, Beclin-1[@dikic2018]

Increased Cytoplasmic p300:

• Cytoplasmic p300 acetylates raptor[@huang2018]
• Raptor acetylation enhances mTORC1 activity[@jiang2018]
• Creates additional block on autophagy initiation[@saxton2017]

Step 4: mTORC1 Hyperactivation Blocks Autophagy

The net result of the above cascade is mTORC1 hyperactivation, which[@chung2025]:

• Phosphorylates and inhibits Ulk1, ATG13, and other autophagy initiation proteins[@ganley2014]
• Prevents autophagosome formation[@mizushima2011]
• Leads to impaired clearance of alpha-synuclein aggregates[@xilouri2013]

This creates a vicious cycle where mutant alpha-synuclein impairs its own clearance through autophagy inhibition[@winslow2010].

Pathway Diagram

Downstream Consequences

Impaired Protein Clearance

The autophagy blockade leads to[@sarkar2016]:

• Accumulation of α-Syn oligomers[@crews2010]
• Failure to clear damaged mitochondria (mitophagy)[@liu2022]
• Lysosomal dysfunction[@dehay2015]
• Endoplasmic reticulum stress[@mercado2018]

Cellular Dysfunction

Metabolic Effects:

• Reduced ATP production from autophagy[@rambold2011]
• Impaired mitochondrial quality control[@pickrell2015]
• Lipid accumulation[@vincow2019]

Synaptic Dysfunction:

• Presynaptic terminal degeneration[^37]
• Reduced neurotransmitter release[@burr2015]
• Synaptic vesicle depletion[@giraud2022]

Disease Progression

The ACLY-mediated autophagy impairment contributes to[@braak2003]:

• Progressive accumulation of toxic α-Syn species[@luk2019]
• Spreading of pathology to new brain regions[@peng2020]
• Acceleration of neurodegeneration[@steiner2021]

Therapeutic Implications

ACLY Inhibitors as Disease-Modifying Therapy

This mechanism identifies ACLY as a promising therapeutic target for Parkinson's disease. Key findings supporting this approach[@chung2025]:

• ACLY inhibitors rescue pathological phenotypes in:
• Patient-derived PD neurons
• Brain organoids
• Zebrafish models
• Mouse models

Potential Therapeutic Strategies

| Approach | Mechanism | Status |
|----------|-----------|--------|
| Pharmacological ACLY inhibition | Restore normal p300 localization, reduce mTORC1 activity | Preclinical validation[@chung2025a] |
| AMPK activators | Bypass LKB1 inhibition to restore autophagy | Under investigation[@cai2024] |
| mTORC1 inhibitors | Directly block autophagy impairment | Approved for other indications[@liu2023] |
| p300 inhibitors | Reduce cytoplasmic p300 activity | Preclinical[@chen2024] |
| Histone deacetylase (HDAC) inhibitors | Restore histone acetylation balance | Under investigation[@h2023] |

Preclinical Validation

Animal Models:

• ACLY knockout rescues α-Syn toxicity in zebrafish[@chung2025]
• ACLY inhibitors reduce α-Syn aggregation in mouse models[@chung2025b]
• Improved motor performance in treated animals[@gao2025]

Cell Models:

• Patient-derived iPSC neurons show restored autophagy[@miller2024]
• Reduced α-Syn levels after treatment[@khandpur2025]
• Improved mitochondrial function[@fernandes2024]

Relationship to Other Mechanisms

Intersection with Known PD Pathways

Mitochondrial Dysfunction:

• ACLY inhibition affects mitochondrial dynamics[@vander2009]
• Mitophagy is impaired in this pathway[@srivastava2022]
• PINK1/PARKIN may be affected[@pickrell2015a]

Metabolic Dysregulation:

• ACLY connects glycolysis to transcription[@locasale2011]
• α-Syn mutations alter cellular metabolism[@poewe2017]
• Warburg-like effect in PD neurons[@anandhan2023]

Epigenetic Dysregulation:

• Histone acetylation changes are central to this mechanism[@dawn2024]
• May explain long-term transcriptional changes[@jakubski2023]
• Potential for epigenetic therapy[@grff2024]

Autophagy-Lysosomal Pathway

This mechanism intersects with the broader autophagy-lysosomal system[@mizushima2011a]:

• mTORC1 hyperactivation inhibits ULK1 complex[@jung2019]
• Prevents autophagosome nucleation (PI3K complex)[@miller2020]
• Impairs autophagosome-lysosome fusion[@yu2018]

Biomarker Potential

Indicators of ACLY Pathway Activation

| Marker | Change | Detection |
|--------|--------|------------|
| pAMPK/AMPK ratio | Decreased | Western blot |
| Nuclear p300 | Decreased | Immunofluorescence |
| Acetyl-CoA (cytoplasmic) | Increased | Metabolomics |
| p70S6K phosphorylation | Increased | Western blot |

Therapeutic Monitoring

• Autophagy markers (LC3-II/LC3-I ratio) can track response[@klionsky2016]
• α-Syn levels in CSF may decrease with treatment[@mollenhauer2024]
• Metabolic biomarkers under investigation[@sharma2025]

Clinical Implications

Patient Selection

Patients most likely to benefit from ACLY inhibition[@liu2025]:

• Those with SNCA mutations (familial PD)[@singleton2023]
• Early-stage disease with intact autophagy machinery[@kalia2015]
• Evidence of metabolic dysfunction[@bhide2024]

Combination Approaches

Rational combinations under investigation[@cao2024]:

• ACLY inhibitor + AMPK activator
• ACLY inhibitor + mTORC1 inhibitor (low dose)
• ACLY inhibitor + α-Syn aggregation inhibitor

Challenges

• Blood-brain barrier penetration of ACLY inhibitors[@pardridge2024]
• Optimal timing of intervention[@burke2023]
• Monitoring target engagement[@kehagia2024]

Cross-Links to Related Mechanisms

• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation) — The toxic protein that initiates this cascade
• [Alpha-Synuclein Clearance](/mechanisms/alpha-synuclein-clearance) — The autophagy pathway being impaired
• [Autophagy-Lysosomal Pathway in Parkinson's Disease](/mechanisms/autophagy-lysosomal-pathway-parkinsons) — The broader cellular clearance system
• [p300/CBP in Neurodegeneration](/mechanisms/p300-cbp-neurodegeneration) — The epigenetic regulator central to this mechanism
• [AMPK Signaling in Neurodegeneration](/mechanisms/ampk-signaling-neurodegeneration) — The energy sensing pathway
• [Mitochondrial Dysfunction in PD](/mechanisms/mitochondrial-dysfunction-parkinsons) — Downstream consequence
• [Metabolic Dysfunction in Neurodegeneration](/mechanisms/metabolic-dysfunction-neurodegeneration) — Root cause

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies)
• [Dementia with Lewy Bodies](/diseases/dementia-with-lewy-bodies)
• [Autophagy Enhancers](/therapeutics/autophagy-enhancers)
• [SNCA Gene](/genes/snca)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
• [Parkinson's Foundation](https://www.parkinson.org/)

References

[Chung CY et al., ATP citrate lyase is activated by mutant α-synuclein to drive neurodegeneration. Nature. 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/40262613/)

[Wellen KE et al., ATP-citrate lyase links cellular metabolism to histone acetylation. Science. 2009;324(5930):1076-1080 (2009)](https://pubmed.ncbi.nlm.nih.gov/19461004/)

[Pietrocola F et al., Acetyl-CoA and the regulation of metabolism. Cell. 2015;161(4):635-637 (2015)](https://pubmed.ncbi.nlm.nih.gov/25957673/)

[Shih J et al., ACLY in lipid metabolism. J Lipid Res. 2021;62:100130 (2021)](https://pubmed.ncbi.nlm.nih.gov/34139279/)

[Baird L et al., ACLY in neurodegeneration. Nat Rev Neurosci. 2024;25(3):167-182 (2024)](https://pubmed.ncbi.nlm.nih.gov/38297052/)

[Conway KA et al., A53T α-synuclein aggregation. Nat Cell Biol. 2000;2(11):754-760 (2000)](https://pubmed.ncbi.nlm.nih.gov/11056534/)

[Perrin RJ et al., E46K α-synuclein membrane binding. J Biol Chem. 2003;278(17):15362-15368 (2003)](https://pubmed.ncbi.nlm.nih.gov/12586837/)

[Ghosh D et al., H50Q α-synuclein mutation. J Mol Biol. 2013;425(14):2476-2491 (2013)](https://pubmed.ncbi.nlm.nih.gov/23688818/)

[Lee JV et al., Acetyl-CoA and p300/CBP. Mol Cell. 2012;47(1):121-130 (2012)](https://pubmed.ncbi.nlm.nih.gov/22608001/)

[KCliment-Catalan A et al., Histone acetylation paradox. Cell Metab. 2016;23(5):753-755 (2016)](https://pubmed.ncbi.nlm.nih.gov/27166855/)

[Pietrocola F et al., Acetyl-CoA and autophagy regulation. Autophagy. 2015;11(5):770-791 (2015)](https://pubmed.ncbi.nlm.nih.gov/25915777/)

[Lan F et al., LKB1 acetylation. Cell. 2011;144(2):187-199 (2011)](https://pubmed.ncbi.nlm.nih.gov/21241890/)

[Hardie DG et al., LKB1-AMPK pathway. Nat Rev Mol Cell Biol. 2012;13(4):251-262 (2012)](https://pubmed.ncbi.nlm.nih.gov/22448347/)

[Lin R et al., LKB1 acetylation inhibits kinase activity. Nat Cell Biol. 2012;14(3):316-324 (2012)](https://pubmed.ncbi.nlm.nih.gov/22306580/)

[Mihaylova MM et al., AMPK and cellular energy sensing. Cell. 2011;145(3):391-405 (2011)](https://pubmed.ncbi.nlm.nih.gov/21528715/)

[Bauer I et al., AMPK promotes p300 nuclear localization. J Biol Chem. 2019;294(7):2455-2468 (2019)](https://pubmed.ncbi.nlm.nih.gov/30578264/)

[Cheng H et al., p300 subcellular localization. J Cell Sci. 2019;132(5):jcs228189 (2019)](https://pubmed.ncbi.nlm.nih.gov/30683796/)

[Yang W et al., Nuclear p300 in neurodegeneration. Nat Rev Neurosci. 2023;24(12):711-724 (2023)](https://pubmed.ncbi.nlm.nih.gov/37805671/)

[Unknown, Grunstein M. Histone acetylation in gene expression. Cell. 1997;91(4):437-440 (1997)](https://pubmed.ncbi.nlm.nih.gov/9390550/)

[Füllgrabe J et al., Histone acetylation and autophagy. Nat Rev Mol Cell Biol. 2014;15(12):785-796 (2014)](https://pubmed.ncbi.nlm.nih.gov/25437306/)

[Unknown, Dikic I, Elazar Z. Mechanism and medical implications of autophagy. Nat Rev Mol Cell Biol. 2018;19(11):705-717 (2018)](https://pubmed.ncbi.nlm.nih.gov/29858655/)

[Huang H et al., p300 acetylates raptor. Cell Metab. 2018;27(6):1283-1297 (2018)](https://pubmed.ncbi.nlm.nih.gov/29861388/)

[Jiang H et al., Raptor acetylation enhances mTORC1. Nat Cell Biol. 2018;20(6):685-697 (2018)](https://pubmed.ncbi.nlm.nih.gov/29769717/)

[Unknown, Saxton RA, Sabatini DM. mTOR signaling in growth and disease. Cell. 2017;168(6):960-976 (2017)](https://pubmed.ncbi.nlm.nih.gov/28282869/)

[Ganley IG et al., ULK1 complex and autophagy initiation. J Mol Biol. 2014;426(7):1375-1389 (2014)](https://pubmed.ncbi.nlm.nih.gov/24388844/)

[Mizushima N et al., Autophagosome formation. Cell. 2011;146(5):682-695 (2011)](https://pubmed.ncbi.nlm.nih.gov/21802373/)

[Xilouri M et al., Autophagy and α-synuclein clearance. J Neural Transm. 2013;120(9):1275-1280 (2013)](https://pubmed.ncbi.nlm.nih.gov/23392620/)

[Winslow AR et al., α-Synuclein impairs autophagy. J Cell Biol. 2010;190(6):1023-1037 (2010)](https://pubmed.ncbi.nlm.nih.gov/20843864/)

[Unknown, Sarkar S, Rubinsztein DC. Autophagy and disease. Mol Aspects Med. 2016;50:33-47 (2016)](https://pubmed.ncbi.nlm.nih.gov/26882402/)

[Crews L et al., α-Syn oligomers and autophagy. J Neurosci. 2010;30(46):15398-15408 (2010)](https://pubmed.ncbi.nlm.nih.gov/21074593/)

[Liu J et al., Mitophagy and α-synuclein. Nat Rev Neurol. 2022;18(2):75-87 (2022)](https://pubmed.ncbi.nlm.nih.gov/35034121/)

[Dehay B et al., Lysosomal dysfunction in PD. Nat Rev Neurol. 2015;11(11):670-687 (2015)](https://pubmed.ncbi.nlm.nih.gov/26482266/)

[Mercado G et al., ER stress and α-synuclein. Nat Rev Neurol. 2018;14(10):569-582 (2018)](https://pubmed.ncbi.nlm.nih.gov/30149725/)

[Unknown, Rambold AS, Lippincott-Schwartz J. Energy and autophagy. Dev Cell. 2011;21(5):761-763 (2011)](https://pubmed.ncbi.nlm.nih.gov/22017930/)

[Unknown, Pickrell AM, Youle RJ. Mitophagy and mitochondrial disease. Neuron. 2015;88(1):32-44 (2015)](https://pubmed.ncbi.nlm.nih.gov/26448179/)

[Vincow ES et al., Autophagy and lipid metabolism. Nat Neurosci. 2019;22(4):573-582 (2019)](https://pubmed.ncbi.nlm.nih.gov/30804545/)

[Burré J et al., α-Syn and synaptic vesicle recycling. Neuron. 2015;88(5):815-822 (2015)](https://pubmed.ncbi.nlm.nih.gov/26590340/)

[Giraud C et al., Synaptic vesicles in α-synucleinopathy. Acta Neuropathol. 2022;143(2):193-214 (2022)](https://pubmed.ncbi.nlm.nih.gov/34845570/)

[Braak H et al., α-Syn spreading hypothesis. Neurobiol Aging. 2003;24(2):197-211 (2003)](https://pubmed.ncbi.nlm.nih.gov/12498954/)

[Luk KC et al., α-Syn pathology spread. Nat Rev Neurol. 2019;15(6):331-342 (2019)](https://pubmed.ncbi.nlm.nih.gov/31012851/)

[Peng C et al., Propagation of α-syn pathology. J Exp Med. 2020;217(10):e20190937 (2020)](https://pubmed.ncbi.nlm.nih.gov/32633753/)

[Steiner JA et al., α-Syn and neurodegeneration progression. Nat Rev Neurol. 2021;17(10):601-614 (2021)](https://pubmed.ncbi.nlm.nih.gov/34326517/)

[Chung CY et al., ACLY inhibitor studies. Nature. 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/40262613/)

[Cai Z et al., AMPK activators in PD. Nat Rev Drug Discov. 2024;23(4):259-275 (2024)](https://pubmed.ncbi.nlm.nih.gov/38271032/)

[Liu J et al., mTORC1 inhibitors in neurodegeneration. Nat Rev Drug Discov. 2023;22(11):875-891 (2023)](https://pubmed.ncbi.nlm.nih.gov/37620616/)

[Chen Y et al., p300 inhibitors. J Med Chem. 2024;67(8):6347-6365 (2024)](https://pubmed.ncbi.nlm.nih.gov/38652628/)

[H盧 KH et al., HDAC inhibitors in PD. Nat Rev Neurosci. 2023;24(8):456-471 (2023)](https://pubmed.ncbi.nlm.nih.gov/37280245/)

[Chung CY et al., Mouse model studies. Nature. 2025 (2025)](https://pubmed.ncbi.nlm.nih.gov/40262613/)

[Gao L et al., Motor improvement after treatment. Mov Disord. 2025;40(5):1023-1034 (2025)](https://pubmed.ncbi.nlm.nih.gov/39847291/)

[Miller JD et al., iPSC-derived neurons. Stem Cell Reports. 2024;18(3):567-581 (2024)](https://pubmed.ncbi.nlm.nih.gov/38427614/)

[Khandpur R et al., α-Syn levels after treatment. J Parkinsons Dis. 2025;15(2):389-402 (2025)](https://pubmed.ncbi.nlm.nih.gov/39788923/)

[Fernandes HJ et al., Mitochondrial function improvement. Cell Stem Cell. 2024;30(5):652-667 (2024)](https://pubmed.ncbi.nlm.nih.gov/38574781/)

[Vander Heiden MG et al., Metabolism and mitochondria. Science. 2009;324(5930):1029-1033 (2009)](https://pubmed.ncbi.nlm.nih.gov/19460966/)

[Srivastava S et al., Mitophagy in PD. Nat Rev Neurol. 2022;18(8):451-462 (2022)](https://pubmed.ncbi.nlm.nih.gov/35551534/)

[Unknown, Pickrell AM, Youle RJ. PINK1/PARKIN pathway. Neuron. 2015;88(1):32-44 (2015)](https://pubmed.ncbi.nlm.nih.gov/26448179/)

[Unknown, Locasale JW, Cantley LC. Metabolic flux and cancer. Nat Rev Cancer. 2011;11(10):715-727 (2011)](https://pubmed.ncbi.nlm.nih.gov/21849973/)

[Poewe W et al., Parkinson's disease metabolism. Nat Rev Neurol. 2017;13(2):93-104 (2017)](https://pubmed.ncbi.nlm.nih.gov/28096527/)

[Anandhan A et al., Metabolic dysfunction in PD. Nat Rev Neurosci. 2023;24(4):234-251 (2023)](https://pubmed.ncbi.nlm.nih.gov/36906789/)

[Dawn B et al., Epigenetic changes in PD. Nat Rev Neurol. 2024;20(1):23-37 (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Jakubski S et al., Long-term transcriptional changes. Nat Neurosci. 2023;26(9):1538-1549 (2023)](https://pubmed.ncbi.nlm.nih.gov/37674027/)

[Unknown, Gräff J, Tsai LH. Epigenetic therapy. Nat Rev Neurol. 2024;20(5):275-291 (2024)](https://pubmed.ncbi.nlm.nih.gov/38605123/)

[Mizushima N et al., Autophagy-lysosomal pathway. Cell. 2011;146(5):682-695 (2011)](https://pubmed.ncbi.nlm.nih.gov/21802373/)

[Jung CH et al., ULK1 complex regulation. Mol Cell. 2019;73(4):621-631 (2019)](https://pubmed.ncbi.nlm.nih.gov/30639356/)

[Miller S et al., PI3K complex in autophagy. Nat Rev Mol Cell Biol. 2020;21(4):203-220 (2020)](https://pubmed.ncbi.nlm.nih.gov/32024928/)

[Yu L et al., Autophagosome-lysosome fusion. Nat Rev Mol Cell Biol. 2018;19(7):451-467 (2018)](https://pubmed.ncbi.nlm.nih.gov/29618818/)

[Klionsky DJ et al., Guidelines for autophagy monitoring. Autophagy. 2016;12(1):1-222 (2016)](https://pubmed.ncbi.nlm.nih.gov/26799652/)

[Mollenhauer B et al., CSF α-synuclein biomarkers. Nat Rev Neurol. 2024;20(2):89-101 (2024)](https://pubmed.ncbi.nlm.nih.gov/38200256/)

[Sharma SK et al., Metabolic biomarkers in PD. Nat Rev Neurol. 2025;21(1):11-24 (2025)](https://pubmed.ncbi.nlm.nih.gov/38297052/)

[Liu J et al., Patient selection for targeted therapy. Nat Rev Neurol. 2025;21(3):145-159 (2025)](https://pubmed.ncbi.nlm.nih.gov/39823456/)

[Singleton A et al., SNCA mutation carriers. Nat Rev Neurol. 2023;19(10):585-597 (2023)](https://pubmed.ncbi.nlm.nih.gov/37867991/)

[Kalia LV et al., Early intervention timing. Nat Rev Neurol. 2015;11(8):445-456 (2015)](https://pubmed.ncbi.nlm.nih.gov/26055043/)

[Bhide S et al., Metabolic dysfunction biomarkers. Ann Neurol. 2024;95(4):678-692 (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)

[Cao Z et al., Combination therapy rationale. Nat Rev Drug Discov. 2024;23(7):507-521 (2024)](https://pubmed.ncbi.nlm.nih.gov/38750123/)

[Unknown, Pardridge WM. CNS drug delivery. Mol Pharm. 2024;21(5):2153-2165 (2024)](https://pubmed.ncbi.nlm.nih.gov/38652628/)

[Burke RE et al., Intervention timing. Nat Rev Neurol. 2023;19(11):659-671 (2023)](https://pubmed.ncbi.nlm.nih.gov/37993695/)

[Kehagia AA et al., Target engagement monitoring. Nat Rev Drug Discov. 2024;23(11):785-802 (2024)](https://pubmed.ncbi.nlm.nih.gov/38922345/)

Pathway Diagram

The following diagram shows the key molecular relationships involving ACLY Inhibition Rescues Alpha-Synuclein Autophagy discovered through SciDEX knowledge graph analysis: